Key Points
- Insider sale: Director Karen Anderson sold 41,076 shares on March 26 at an average price of $30.12 for a total of $1.237 million, cutting her stake by 39.82% and leaving her with 62,085 shares (~$1.87M).
- Stock snapshot: CNTA opened at $28.70 and trades in a one‑year range of $9.60–$30.58, with a market cap of $4.19 billion, a negative P/E (‑15.68) and strong liquidity ratios (quick and current ratios ~10.56).
- Analyst sentiment: The consensus rating is "Buy" with an average price target of $39.80, and several firms recently raised targets (e.g., Truist to $38, B. Riley to $42) while ratings breakdown is 2 Strong Buy, 10 Buy, 1 Sell.
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) insider Karen Anderson sold 41,076 shares of the stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the completion of the sale, the insider owned 62,085 shares of the company's stock, valued at approximately $1,870,000.20. The trade was a 39.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Centessa Pharmaceuticals Stock Performance
Shares of Centessa Pharmaceuticals stock opened at $28.70 on Friday. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $9.60 and a one year high of $30.58. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The business's 50 day moving average price is $25.85 and its 200 day moving average price is $25.07. The company has a market cap of $4.19 billion, a price-to-earnings ratio of -15.68 and a beta of 1.55.
Analyst Ratings Changes
A number of research firms have recently weighed in on CNTA. Truist Financial increased their price target on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a "buy" rating in a report on Thursday, January 29th. B. Riley Financial boosted their price target on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a "buy" rating in a research note on Monday, December 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. TD Cowen reaffirmed a "buy" rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Finally, Wolfe Research began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, February 24th. They issued an "outperform" rating and a $40.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $39.80.
Get Our Latest Stock Report on CNTA
Institutional Trading of Centessa Pharmaceuticals
Several hedge funds have recently made changes to their positions in CNTA. TD Waterhouse Canada Inc. acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in Centessa Pharmaceuticals in the 4th quarter valued at approximately $36,000. T. Rowe Price Investment Management Inc. boosted its stake in shares of Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company's stock valued at $39,000 after acquiring an additional 1,516 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Centessa Pharmaceuticals by 42.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company's stock valued at $85,000 after buying an additional 1,008 shares during the last quarter. Finally, Knott David M Jr acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth $100,000. Institutional investors and hedge funds own 82.01% of the company's stock.
About Centessa Pharmaceuticals
(
Get Free Report)
Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.
Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
